Black Diamond Therapeutics to present Phase 2 trial results for BDTX-1535 in recurrent EGFRm NSCLC on Sept 23.

Black Diamond Therapeutics will host a webcast on September 23 at 8:00 a.m. ET to reveal initial Phase 2 clinical trial results for BDTX-1535, targeting recurrent EGFRm NSCLC. The event will be available on their website, with a replay afterwards. The company focuses on therapies for cancer mutations and is advancing two programs: BDTX-1535 for NSCLC and glioblastoma, and BDTX-4933 for solid tumors with specific genetic alterations.

September 22, 2024
6 Articles

Further Reading